Trilogy Capital Inc. Buys Shares of 1,026 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Trilogy Capital Inc. bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,026 shares of the pharmaceutical company’s stock, valued at approximately $429,000.

Other large investors also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Managment Co. acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $25,000. Annapolis Financial Services LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its holdings in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 33 shares during the period. ICA Group Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $28,000. Finally, Fortitude Family Office LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VRTX. Redburn Atlantic began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $545.00 price objective on the stock. Piper Sandler boosted their price objective on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $462.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $448.61.

Insider Transactions at Vertex Pharmaceuticals

In other news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total value of $1,089,840.00. Following the completion of the transaction, the chief marketing officer now owns 32,379 shares of the company’s stock, valued at $15,477,162. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Edward Morrow Atkinson III sold 7,288 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total value of $3,483,664.00. Following the completion of the transaction, the executive vice president now owns 15,972 shares in the company, valued at approximately $7,634,616. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the completion of the transaction, the chief marketing officer now owns 32,379 shares of the company’s stock, valued at approximately $15,477,162. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,366 shares of company stock valued at $13,058,787. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock traded down $3.79 during trading hours on Friday, reaching $468.72. 3,234,634 shares of the stock were exchanged, compared to its average volume of 1,247,780. The company has a market cap of $120.95 billion, a P/E ratio of 30.42, a price-to-earnings-growth ratio of 2.41 and a beta of 0.41. The company has a current ratio of 3.50, a quick ratio of 3.29 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a twelve month low of $335.82 and a twelve month high of $486.42. The stock has a 50 day moving average of $444.89 and a two-hundred day moving average of $426.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The firm had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.